Arihant Superstructures Limited (NSE:ARIHANTSUP)

Theseus Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	546.76	692.25	426.75	413.76	111.71
Depreciation & Amortization	23.69	21.86	19.4	17.16	20.14
Other Amortization	-	0.02	0.13	0.18	0.25
Loss (Gain) From Sale of Assets	-2.43	-	-	-0.16	0.16
Loss (Gain) on Equity Investments	-	0	-0.01	-0.01	-
Other Operating Activities	266.02	234.41	252.64	209.37	269.45
Change in Inventory	-1,733	-713.22	-368.32	-922.67	333.92
Change in Other Net Operating Assets	-879.07	-1,498	-448.61	489.21	469.59
Operating Cash Flow	-1,778	-1,263	-118	206.85	1,205
Operating Cash Flow Growth	-	-	-	-82.84%	374.30%
Capital Expenditures	-762.62	-12.13	-31.1	-19.74	-14.88
Investment in Securities	-57.8	-0	-2.3	-0.01	-11.26
Other Investing Activities	23.72	61.6	15.3	11.86	18.72
Investing Cash Flow	-796.7	49.47	-18.09	-7.88	-7.43
Long-Term Debt Issued	2,880	1,455	325.83	37.59	-
Long-Term Debt Repaid	-	-	-	-	-911.7
Total Debt Repaid	-	-	-	-	-911.7
Net Debt Issued (Repaid)	2,880	1,455	325.83	37.59	-911.7
Common Dividends Paid	-12.49	-5.21	-	-	-
Other Financing Activities	-260.58	-165.76	-256.43	-210.31	-280.96
Financing Cash Flow	2,606	1,284	69.4	-172.72	-1,193
Miscellaneous Cash Flow Adjustments	-	0.02	-	0	0
Net Cash Flow	31.35	70.86	-66.7	26.25	5.15
Free Cash Flow	-2,541	-1,275	-149.1	187.11	1,190
Free Cash Flow Growth	-	-	-	-84.28%	388.63%
Free Cash Flow Margin	-50.94%	-25.28%	-3.83%	5.65%	44.07%
Free Cash Flow Per Share	-44.34	-30.98	-3.62	4.55	28.92
Cash Interest Paid	404.81	259.85	256.43	210.31	280.96
Cash Income Tax Paid	99.23	186.16	80.29	60.86	81.36
Levered Free Cash Flow	-2,926	-1,638	-452.01	-97.21	825.59
Unlevered Free Cash Flow	-2,673	-1,476	-291.74	34.23	1,001
Change in Net Working Capital	2,570	2,144	752.86	388.42	-708.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.